Comparison of laparoscopic and mini incision open donor nephrectomy: single blind, randomised controlled clinical trial
BMJ 2006; doi: https://doi.org/10.1136/bmj.38886.618947.7C (Published 17 July 2006) Cite this as: BMJ 2006;:bmj;bmj.38886.618947.7Cv1
Data supplement
Quality of Life (SF-36) and Fatigue (MFI-20) of donors at baseline and during 1,3,6 and 12 months follow-up. [As supplied by authors]
Laparoscopic donor nephrectomy (LDN) versus open donor nephrectomy (ODN).
Data are displayed as mean (SD). 95% confidence intervals and P-values are given for the estimated difference after adjustment for gender, age and baselline.
Abbreviations; SF-36 short-form 36, PF physphysical function, RP role physical, BP bodily pain, GH general health, VI vitality, SF social functioning,
RE role emotional, MH mental health
MFI-20 multi dimensional fatigue inventory-20, GF general fatigue, PF physical fatigue, RA reduced activities, RM reduced motivation, MF mental fatigue
Baseline
One month
Three months
Six months
Twelve months
LDN
(n=50)
ODN
(n=50)
LDN
(n=48)
ODN
(n=49)
CI
P-
value
LDN
(n=46)
ODN
(n=47)
CI
P-
value
LDN
(n=46)
ODN
(n=46)
CI
P-
value
LDN
(n=45)
ODN
(n=44)
CI
P-
value
SF-36
PF
RP
BP
GH
VI
SF
RE
MH
94.8 (9.8)
96.0 (13.7)
95.5 (10.8)
85.3 (13.4)
83.7 (9.7)
95.0 (9.4)
91.3 (23.1)
68.2 (12.7)
90.3 (15.5)
84.1 (33.7)
94.4 (16.0)
84.8 (14.2)
76.2 (18.1)
85.3 (18.2)
88.7 (25.3)
68.2 (14.8)
80.0 (19.3)
48.4 (41.1)
80.1 (21.6)
84.7 (12.6)
72.5 (18.8)
83.9 (19.6)
81.9 (33.7)
67.7 (10.1)
69.8 (16.9)
36.2 (39.9)
74.7 (22.7)
77.1 (17.1)
61.0 (20.1)
71.4 (26.0)
58.0 (45.2)
61.8 (13.7)
1.4 to 16.5
-7.0 to 26.8
-2.8 to 15.3
2.5 to 14.7
-1.6 to 14.0
0.3 to 19.8
3.8 to 36.5
2.1 to 11.8
0.02
0.25
0.17
0.006
0.12
0.04
0.02
0.005
93.6 (10.7)
87.2 (30.9)
92.3 (16.0)
85.0 (14.7)
78.8 (16.1)
93.9 (13.5)
90.9 (26.3)
68.1 (11.8)
86.9 (16.4)
72.3 (40.8)
89.8 (20.1)
79.9 (20.5)
70.0 (21.6)
84.6 (21.7)
78.8 (38.1)
64.4 (16.6)
-0.3 to 10.1
-3.6 to 26.0
-4.8 to 9.3
-0.7 to 13.3
2.5 to 12.2
-1.2 to 13.8
-2.4 to 23.3
-1.0 to 10.3
0.06
0.14
0.53
0.08
0.20
0.10
0.11
0.10
94.9 (8.1)
91.7 (22.6)
95.7 (9.5)
87.6 (14.7)
81.9 (17.7)
94.4 (12.7)
95.6 (15.2)
70.1 (11.8)
86.8 (19.8)
82.6 (33.3)
92.3 (14.8)
81.6 (17.9)
71.9 (21.1)
85.9 (17.0)
87.6 (28.2)
65.5 (14.4)
1.1 to 12.6
- 5.3 to 17.8
- 0.9 to 8.7
-0.5 to 12.3
-1.1 to 13.4
-0.8 to 11.7
- 1.4 to 18.8
-0.5 to 9.7
0.02
0.29
0.11
0.07
0.09
0.09
0.09
0.08
95.8 (10.8)
92.2 (26.0)
97.5 (8.6)
85.7 (15.9)
82.2 (13.2)
96.7 (9.0)
100.0 (0.0)
68.6 (12.7)
87.0 (21.1)
85.7 (32.7)
91.7 (19.6)
83.3 (18.1)
72.1 (19.7)
86.9 (22.7)
83.8 (35.8)
67.2 (14.8)
0.7 to 13.7
-6.6 to 19.3
-0.6 to 11.9
-1.1 to 12.5
-0.7 to 13.5
0.5 to 14.3
4.1 to 25.3
-1.3 to 9.5
0.03
0.33
0.08
0.10
0.03
0.04
0.007
0.13
MFI-20
GF
PF
RA
RM
MF
5.5 (2.0)
5.0 (1.5)
6.5 (2.7)
6.0 (2.1)
6.6 (3.1)
6.6 (3.6)
5.9 (3.1)
7.1 (3.4)
6.5 (2.9)
8.1 (4.6)
9.8 (4.8)
8.7 (3.9)
10.1 (4.4)
7.2 (3.3)
7.8 (4.3)
11.7 (4.5)
11.1 (4.5)
11.0 (4.4)
8.4 (4.3)
8.7 (4.9)
-3.0 to 0.7
-3.7 to -0.3
-2.4 to 1.3
-2.6 to 0.6
-1.7 to 1.5
0.22
0.02
0.57
0.20
0.93
8.2 (3.9)
7.0 (3.5)
7.3 (3.9)
6.5 (3.6)
7.1 (4.7)
9.3 (4.9)
7.6 (3.9)
7.8 (4.0)
7.4 (4.4)
8.3 (4.5)
-1.9 to 1.3
-1.9 to 1.2
-1.9 to 1.2
-2.1 to 1.0
-1.9 to 1.3
0.70
0.66
0.67
0.49
0.71
7.4 (4.2)
5.9 (2.8)
6.4 (3.6)
5.6 (3.0)
6.4 (3.5)
8.9 (4.4)
7.4 (4.1)
7.6 (4.4)
6.8 (4.0)
8.0 (4.4)
-2.2 to 1.0
-2.6 to 0.1
-2.1 to 0.8
-2.2 to 0.4
-1.9 to 0.4
0.47
0.08
0.37
0.17
0.18
6.9 (3.6)
5.7 (2.2)
6.0 (2.7)
5.9 (2.7)
6.4 (3.5)
8.2 (4.4)
7.3 (3.9)
7.6 (4.2)
7.5 (4.5)
8.5 (4.4)
-2.1 to 1.0
-2.5 to 0.0
-2.2 to 0.2
-2.3 to 0.2
-2.2 to 0.3
0.46
0.05
0.10
0.09
0.14
Related articles
- Editorial Published: 27 July 2006; BMJ 333 doi:10.1136/bmj.333.7561.209
- This Week In The BMJ Published: 27 July 2006; BMJ 333 doi:10.1136/bmj.333.7561.0
See more
- Generics have a chequered recent historyBMJ December 05, 2016, 355 i6527; DOI: https://doi.org/10.1136/bmj.i6527
- An older man with thoracic back painBMJ November 23, 2016, 355 i5786; DOI: https://doi.org/10.1136/bmj.i5786
- Potential role for BCG in treatment of autoimmune diseasesBMJ November 21, 2016, 355 i6091; DOI: https://doi.org/10.1136/bmj.i6091
- Risks of duloxetine for stress incontinence outweigh benefits, say researchersBMJ November 15, 2016, 355 i6103; DOI: https://doi.org/10.1136/bmj.i6103
- HaematospermiaBMJ November 10, 2016, 355 i5124; DOI: https://doi.org/10.1136/bmj.i5124
Cited by...
- Towards a standardised informed consent procedure for live donor nephrectomy: the PRINCE (Process of Informed Consent Evaluation) project--study protocol for a nationwide prospective cohort study
- What's the Best Technique for Living-Donor Nephrectomy?
- Quality of life after donor nephrectomy